PER-094-09已完成未知
A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy
ELI LILLY AND COMPANY,0 个研究点目标入组 31 人开始时间: 2009年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 75（—）
入选标准
- •You must be between the ages of 18 and 75
- •You must have active RA
- •Qualifications Specific to the bDMARD-naive Population: You must be regularly using methotrexate (MTX) for at least 12 weeks before your participation in this study
- •Qualifications Specific to the TNFα-IR Population: You must have been treated with at least 1 biologic TNFα inhibitor therapy and either had an insufficient response to at least 3 months of treatment OR have been intolerant of such treatment
- •You must be regularly using at least 1 conventional DMARD in a stable treatment regimen
排除标准
- •You are concomitantly using non-steroidal anti-inflammatory drugs (NSAIDS), unless you are on a stable dose within the last 2 weeks
- •You are a woman who is lactating or breast feeding
- •You have donated more than 300 milliliters (mL) of blood within the last month
- •You have received glucocorticoid administered by intra-articular, intramuscular, or intravenous injection or oral corticosteroids at an average daily dose of greater than 10 mg per day of prednisone or its equivalent within the last 4 weeks
- •You had surgery on a joint that is to be assessed in the study within 2 months of study enrollment, or will require such during the study
- •You have another serious disorder or illness
- •You suffered a serious bacterial infection (for example, pneumonia, cellulitis, or bone or joint infections) within the last 3 months
- •You have a history of uncontrolled high blood pressure
- •You have clinical laboratory test results at entry that are outside the normal reference range
- •You are an employee of the clinic or you are an immediate family member of an employee of the clinic. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
- •You are currently participating in or were discontinued within the last 30 days from another clinical trial involving an investigational drug
- •If you are a woman and you could become pregnant during this study, you must talk to the study doctor about the birth control that you will use to avoid getting pregnant during the study.
- •If you are a post-menopausal woman, you must be at least 45 years of age and have not menstruated for the last 12 months
- •If you are a post-menopausal woman between 40 and 45 years of age, test negative for pregnancy, and have not menstruated during the last 12 months only, you must have an additional blood test to see if you can participate.
- •If you are male, you must agree to reduce the risk of your female partner becoming pregnant during the study.
研究者
相似试验
进行中（未招募）
不适用
A Study in Patients with Rheumatoid ArthritisMedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2009-009696-34-DEEli Lilly and Company648
已完成
2 期
A Study in Patients With Rheumatoid ArthritisCTRI/2009/091/000777Eli Lilly372
进行中（未招募）
不适用
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate TherapyRheumatoid arthritisEUCTR2008-004894-16-PLEli Lilly and Company limited150
进行中（未招募）
不适用
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate TherapyRheumatoid arthritisEUCTR2008-004894-16-CZEli Lilly and Company limited150
进行中（未招募）
1 期
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate TherapyRheumatoid arthritisEUCTR2008-004894-16-HUEli Lilly and Company limited150